Skip to main content
07/06/2022

Two Vall d’Hebron research papers win at the "Archivos de Bronconeumología" 2022 awards

2022_Premios_Archivo_Bronconeumología
Premis_Archivos_de_Bronconeumología_2022

07/06/2022

The study for the ciliary dyskinesia diagnosis led by the VHIR’s Growth and Development Group has been proclaimed the best basic-research article, while EPISCAN II, in which Dr. Miravitlles has participated, has won the award for the most cited original article in 2021.

The "Archivos de Bronconeumología 2022" awards have distinguished two investigations by Vall d’Hebron Research Institute’s (VHIR) researchers. The awards have been given by the Spanish Pneumology and Thoracic Surgery Society (SEPAR) national congress held this June. The award distinguishes the best articles published in the official journal of this scientific society.

This year, the award for the best basic-research article has been for the study "Application of a genetic panel for the genetic diagnosis of primary ciliary dyskinesia” carried out and coordinated by the VHIR’ Growth and Development Group, led by Dr. Antonio Moreno, head of the Allergies, Pediatric Pneumology and Cystic Fibrosis Unit at the Vall d’Hebron University Hospital. This multicentric study included patients from Spain who were suspected of suffering from primary ciliary dyskinesia (PCD).

PCD is a rare disease characterized by an alteration of the ciliary structure that prevents the proper function of respiratory secretions. There is not currently a definitive diagnostic tool, instead, a combination of expensive and difficult tests is done. The study has created a high-performance genetic panel, as it has diagnosed 81% of the patients studied, without giving any false positives.

Besides, the study "Prevalence and determinants of COPD in Spain: EPISCAN II" has won the award for the original article most cited in 2021. EPISCAN II is a population-based epidemiological study driven by the pharmaceutical company GSK, whose aim is to investigate the prevalence and causes of Chronic obstructive pulmonary disease (COPD) in Spain. There were 12 hospitals in the study with Vall d'Hebron as the reference hospital of Catalonia. Dr. Miravitlles is part of the scientific committee and is one of the main authors of this study. Other members of the VHIR’s Pneumology Research Group, led by Dr. Ferrer, head of the Vall d’Hebron Pneumology Service and co-director of the aforementioned research group, have also participated in the study.

In total there were 9,433 participants, 53% women and an average age of 60, of whom 11.8% had COPD. The study showed that COPD is one of the most prevalent diseases in the general population and at the same time one of the most underdiagnosed, (three out of four affected had no medical diagnosis).

The "Archivos de Bronconeumología" awards have been held since 2016 within the framework of the national congress of the SEPAR. The SEPAR brings together over 5,200 pneumologists, thoracic surgeons and other respiratory health professionals in Spain.

The award distinguishes the best articles published in the official journal of this scientific society.

Related news

Vall d'Hebron participated in the study in which more than half of the patients who received treatment with bacteriophages experienced significant improvements

La recerca és fonamental per contrarestar els efectes de la pol·lució, que segons l’AEMPS, va ser la causa de més de 300.000 morts prematures a la UE el 2020.

Pulmonary hypertension is a risk factor for patients who need surgery and, therefore, defining strategies for its management is important to allow a favorable clinical evolution.

Related professionals

Marc Miravitlles Fernández

Marc Miravitlles Fernández

Main researcher
Pneumology
Read more
Jaume Ferrer Sancho

Jaume Ferrer Sancho

Head of group
Pneumology
Read more
Antonio Moreno Galdó

Antonio Moreno Galdó

Head of group
Growth and Development
Read more
Ignacio Iglesias Serrano

Ignacio Iglesias Serrano

Predoctoral researcher
Growth and Development
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.